{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:50:16Z","timestamp":1794369016278,"version":"4.9.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.leukres.2025.107919","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T23:49:11Z","timestamp":1752623351000},"page":"107919","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control study"],"prefix":"10.1016","volume":"157","author":[{"given":"Andreas","family":"Reiter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-4473","authenticated-orcid":false,"given":"Iv\u00e1n","family":"\u00c1lvarez-Twose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti H.","family":"Radia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0767-1504","authenticated-orcid":false,"given":"Johannes","family":"L\u00fcbke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-8314","authenticated-orcid":false,"given":"Priyanka J.","family":"Bobbili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3490-648X","authenticated-orcid":false,"given":"Aolin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u0161a","family":"Dimitrijevi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Schwaab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilene A.","family":"Galinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1277-7699","authenticated-orcid":false,"given":"Cecelia","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4178-8909","authenticated-orcid":false,"given":"Priya","family":"Sriskandarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1295-5870","authenticated-orcid":false,"given":"Manasi","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teshawna","family":"Badu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8010-4296","authenticated-orcid":false,"given":"Selvam R.","family":"Sendhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.leukres.2025.107919_bib1","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk. Res"},{"issue":"6","key":"10.1016\/j.leukres.2025.107919_bib2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur. J. Clin. Invest"},{"issue":"11","key":"10.1016\/j.leukres.2025.107919_bib3","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2025.107919_bib4","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000646","article-title":"Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal","volume":"5","author":"Valent","year":"2021","journal-title":"HemaSphere"},{"issue":"9","key":"10.1016\/j.leukres.2025.107919_bib5","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1016\/j.jaip.2020.05.005","article-title":"Importance of adequate diagnostic workup for correct diagnosis of advanced systemic mastocytosis","volume":"8","author":"Schwaab","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pr."},{"issue":"23","key":"10.1016\/j.leukres.2025.107919_bib6","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2025.107919_bib7","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","article-title":"Mast cell leukemia","volume":"121","author":"Georgin-Lavialle","year":"2013","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.leukres.2025.107919_bib8","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.leukres.2025.107919_bib9","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3324\/haematol.2017.163964","article-title":"The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm","volume":"102","author":"Jawhar","year":"2017","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.leukres.2025.107919_bib10","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2025.107919_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","article-title":"The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis","volume":"93","author":"Erben","year":"2014","journal-title":"Ann. Hematol."},{"issue":"5","key":"10.1016\/j.leukres.2025.107919_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052562","article-title":"Adverse prognostic impact of the KIT D816V transcriptional activity in advanced systemic mastocytosis","volume":"22","author":"Naumann","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.leukres.2025.107919_bib13","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41375-019-0450-8","article-title":"Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis","volume":"33","author":"Lubke","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2025.107919_bib14","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/all.15584","article-title":"KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes","volume":"78","author":"Navarro-Navarro","year":"2023","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.leukres.2025.107919_bib15","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.23672","article-title":"Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis","volume":"89","author":"Kristensen","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2025.107919_bib16","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat. Med"},{"key":"10.1016\/j.leukres.2025.107919_bib17","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: Interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat. Med"},{"key":"10.1016\/j.leukres.2025.107919_bib18","unstructured":"United States Food and Drug Administration. FDA approves avapritinib for advanced systemic mastocytosis. Accessed July 30, 2021, \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-avapritinib-advanced-systemic-mastocytosis\u3009."},{"key":"10.1016\/j.leukres.2025.107919_bib19","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: AYVAKIT (avapritinib). Accessed October 15, 2021, \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212608s007lbl.pdf\u3009."},{"key":"10.1016\/j.leukres.2025.107919_bib20","unstructured":"European Medicines Agency. Ayvakyt (avapritinib). Accessed June 15, 2022, \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ayvakyt\u3009."},{"issue":"6","key":"10.1016\/j.leukres.2025.107919_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000606","article-title":"European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis","volume":"4","author":"Tzogani","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.leukres.2025.107919_bib22","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: RYDAPT (midostaurin). Accessed October 15, 2021, \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/207997s000lbl.pdf\u3009."},{"key":"10.1016\/j.leukres.2025.107919_bib23","unstructured":"Rydapt: EPAR - Product Information. October 25, 2017. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rydapt-epar-product-information_en.pdf\u3009."},{"issue":"12","key":"10.1016\/j.leukres.2025.107919_bib24","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.leukres.2025.107919_bib25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","article-title":"Treatment of systemic mast-cell disease with cladribine","volume":"344","author":"Tefferi","year":"2001","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2025.107919_bib26","first-page":"JCO2101849","article-title":"Superior efficacy of midostaurin over cladribine in advanced systemic mastocytosis: a registry-based analysis","author":"L\u00fcbke","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.107919_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-022-01615-z","article-title":"Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis","author":"Reiter","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107919_bib28","unstructured":"Retrospective study assessing the effect of avapritinib versus best available therapy in patients with AdvSM. ClinicalTrials.gov identifier: NCT04695431. Updated January 10, 2022. \u3008https:\/\/www.clinicaltrials.gov\/study\/NCT04695431\u3009."},{"issue":"31","key":"10.1016\/j.leukres.2025.107919_bib29","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1200\/JCO.19.00640","article-title":"MARS: mutation-adjusted risk score for advanced systemic mastocytosis","volume":"37","author":"Jawhar","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.leukres.2025.107919_bib30","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.2019000932","article-title":"New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis","volume":"135","author":"Reiter","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2025.107919_bib31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","article-title":"Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers","volume":"130","author":"Jawhar","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2025.107919_bib32","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2025.107919_bib33","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","article-title":"International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study","volume":"6","author":"Sperr","year":"2019","journal-title":"Lancet Haematol."},{"issue":"7","key":"10.1016\/j.leukres.2025.107919_bib34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/aje\/kwq439","article-title":"Doubly robust estimation of causal effects","volume":"173","author":"Funk","year":"2011","journal-title":"Am. J. Epidemiol."},{"issue":"28","key":"10.1016\/j.leukres.2025.107919_bib35","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat. Med"},{"key":"10.1016\/j.leukres.2025.107919_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26498","article-title":"Midostaurin therapy for advanced systemic mastocytosis: mayo clinic experience in 33 consecutive cases","author":"Singh","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2025.107919_bib37","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.19463.1","article-title":"Recent advances in the understanding and therapeutic management of mastocytosis","volume":"8","author":"Rossignol","year":"2019","journal-title":"F1000Res"},{"issue":"2","key":"10.1016\/j.leukres.2025.107919_bib38","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.leukres.2025.107919_bib39","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s00277-023-05180-y","article-title":"Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis","volume":"102","author":"Lubke","year":"2023","journal-title":"Ann. Hematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625002796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625002796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:02:43Z","timestamp":1772762563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625002796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":39,"alternative-id":["S0145212625002796"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107919","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107919","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107919"}}